rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Bio-Rad Laboratories, Inc.

BIO · NYSE

Health CareLife-science toolsLeadingAI

BIO stood above a rising 150-day average in 26 of the last 52 weekly readings, including each of the last 11 weeks. It is 11.6% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
11 in a row
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$485K
Officials’ trades on record
21
Institutions holding
370 (+10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 26 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$714K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

21 disclosed lines: House 17, Senate 3, executive 1; 7 people.

WhoDidAmountTraded
Arjun Mody Executive branch: Office of Government EthicsSocial Security Administrationsold$1k–$15k30 Jan 2026filed 10 Apr 2026
Lois Frankel House: U.S. House ClerkFL22sold$1k–$15k8 Sep 2023filed 10 Oct 2023
Lois Frankel House: U.S. House ClerkFL22bought$1k–$15k29 Jun 2023filed 28 Jul 2023
Lois Frankel House: U.S. House ClerkFL22bought$1k–$15k28 Jun 2023filed 28 Jul 2023
Susie Lee House: U.S. House ClerkNV03soldjoint$1k–$15k30 Nov 2022filed 29 Dec 2022
Tommy Tuberville Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k30 Mar 2022filed 8 Apr 2022
Tommy Tuberville Senate: U.S. Senate eFDSenatorboughtjoint$1k–$15k29 Mar 2021filed 23 Jul 2021
Susie Lee House: U.S. House ClerkNV03sold$1k–$15k5 Jan 2021filed 10 Feb 2021
Susie Lee House: U.S. House ClerkNV03sold$1k–$15k2 Oct 2020filed 8 Dec 2020
Susie Lee House: U.S. House ClerkNV03sold$1k–$15k27 May 2020filed 15 Jun 2020
Susie Lee House: U.S. House ClerkNV03sold$1k–$15k7 Apr 2020filed 15 Jun 2020
Susie Lee House: U.S. House ClerkNV03sold$1k–$15k27 Dec 2019filed 16 Jan 2020

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 2
WhoDidSharesTraded
Eva Anette EngelhardtEVP, President, CDGsold550at $246.5411 May 2026filed 13 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders370+10 on the quarter
New · exited63 · 53
Reported value$5.5B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
First Eagle Investment Management, LLCadded · filed 5 Aug 20262,606,219$765.2M+3,447+0.1%
BlackRock, Inc.added · filed 7 Aug 20261,698,929$498.8M+18,869+1.1%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 2026944,548$277.3M-144,775−13.3%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026826,972$242.8M-4,193−0.5%
ARIEL INVESTMENTS, LLCadded · filed 14 Aug 2026816,751$239.8M+30,790+3.9%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026816,198$239.6M-12,988−1.6%
EARNEST PARTNERS LLCreduced · filed 13 Aug 2026580,752$170.5M-7,979−1.4%
STATE STREET CORPadded · filed 7 Aug 2026571,762$167.9M+12,192+2.2%
BANK OF AMERICA CORPadded · filed 14 Aug 2026490,412$144.0M+45,455+10.2%
Capital World Investorsadded · filed 12 Aug 2026462,457$135.8M+12,457+2.8%
31 Mar 2023 – 30 Jun 2026
341379417Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Courtney C. Enloe Company insiderEVP, General Counsel & Sec · last 6 Sep 20260 · 0
Eva Anette Engelhardt Company insiderEVP, President, CDG · last 6 Sep 20260 · 1
James Barry Company insiderEVP, President, LSG · last 6 Sep 20260 · 2
Norman D. Schwartz Company insiderChairman & CEO · last 6 Sep 20260 · 3
Roop Kalyan Lakkaraju Company insiderEVP, Chief Financial Officer · last 6 Sep 20260 · 0
Schwartz Allison Company insiderDirector · last 6 Sep 20260 · 0
Sedat Evran Company insiderEVP, Global Supply Chain · last 6 Sep 20260 · 0
Jonathan P. DiVincenzo Company insiderPresident & COO · last 5 Sep 20260 · 0
Rajat Mehta Company insiderEVP, GBL Commercial Operations · last 5 Sep 20260 · 0
Arnold A. Pinkston Company insiderDirector · last 21 Apr 20260 · 0
Greg K. Hinckley Company insiderDirector · last 21 Apr 20261 · 0
Jeffrey L. Edwards Company insiderDirector · last 21 Apr 20260 · 0

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202551.9%
Operating profit marginFY 2025 · to 31 Dec 20251.8%
Free cash flow marginFY 2025 · to 31 Dec 202514.5%
Return on capital employedFY 2025 · to 31 Dec 20250.5%
Cash conversionFY 2025 · to 31 Dec 202570.0%
Debt to equityFY 2025 · to 31 Dec 20250.16×
Interest coverFY 2025 · to 31 Dec 20250.96×
Research spendFY 2025 · to 31 Dec 202510.7%
Revenue growthFY 2025 · to 31 Dec 20250.7%
Earnings per share growthFY 2024 · to 31 Dec 2024-210%
Share count trendFY 2025 · to 31 Dec 2025-3.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$529.8M

Analyst forecasts

No analyst forecasts yet.